The Real-World Effectiveness of Fluvoxamine Therapy in Mild to Moderate COVID-19 Patients; a Historical Cohort Study (Fluvoxa Trial)

{ 'indexed': {'date-parts': [[2023, 10, 8]], 'date-time': '2023-10-08T19:15:19Z', 'timestamp': 1696792519868}, 'reference-count': 30, 'publisher': 'Elsevier BV', 'license': [ { 'start': { 'date-parts': [[2023, 10, 1]], 'date-time': '2023-10-01T00:00:00Z', 'timestamp': 1696118400000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'}, { 'start': { 'date-parts': [[2023, 10, 4]], 'date-time': '2023-10-04T00:00:00Z', 'timestamp': 1696377600000}, 'content-version': 'vor', 'delay-in-days': 3, 'URL': 'http://creativecommons.org/licenses/by-nc-nd/4.0/'}], 'funder': [ { 'DOI': '10.13039/100016175', 'name': 'Chulabhorn Royal Academy', 'doi-asserted-by': 'publisher'}], 'content-domain': { 'domain': [ 'clinicalkey.fr', 'clinicalkey.jp', 'clinicalkey.es', 'clinicalkey.com.au', 'clinicalkey.com', 'elsevier.com', 'sciencedirect.com'], 'crossmark-restriction': True}, 'published-print': {'date-parts': [[2023, 10]]}, 'DOI': '10.1016/j.jiph.2023.10.010', 'type': 'journal-article', 'created': {'date-parts': [[2023, 10, 7]], 'date-time': '2023-10-07T00:52:22Z', 'timestamp': 1696639942000}, 'update-policy': 'http://dx.doi.org/10.1016/elsevier_cm_policy', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'The Real-World Effectiveness of Fluvoxamine Therapy in Mild to Moderate COVID-19 Patients; a ' 'Historical Cohort Study (Fluvoxa Trial)', 'prefix': '10.1016', 'author': [ { 'ORCID': 'http://orcid.org/0000-0001-7256-9982', 'authenticated-orcid': False, 'given': 'Taweegrit', 'family': 'Siripongboonsitti', 'sequence': 'first', 'affiliation': []}, {'given': 'Kriangkrai', 'family': 'Tawinprai', 'sequence': 'additional', 'affiliation': []}, {'given': 'Paruspak', 'family': 'Payoong', 'sequence': 'additional', 'affiliation': []}, {'given': 'Nithi', 'family': 'Mahanonda', 'sequence': 'additional', 'affiliation': []}], 'member': '78', 'reference': [ { 'key': '10.1016/j.jiph.2023.10.010_bib1', 'doi-asserted-by': 'crossref', 'article-title': 'A novel coronavirus from patients with pneumonia in China, 2019', 'author': 'Zhu', 'year': '2020', 'journal-title': 'New England Journal of Medicine', 'DOI': '10.1056/NEJMoa2001017'}, { 'issue': '13', 'key': '10.1016/j.jiph.2023.10.010_bib2', 'doi-asserted-by': 'crossref', 'first-page': '1239', 'DOI': '10.1001/jama.2020.2648', 'article-title': 'Characteristics of and important lessons from the coronavirus disease ' '2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases ' 'from the Chinese Center for Disease Control and Prevention', 'volume': '323', 'author': 'Wu', 'year': '2020', 'journal-title': 'Jama'}, { 'issue': '1', 'key': '10.1016/j.jiph.2023.10.010_bib3', 'doi-asserted-by': 'crossref', 'DOI': '10.1002/jmv.28231', 'article-title': 'Global case fatality rate from COVID-19 has decreased by 96.8% during ' '2.5 years of the pandemic', 'volume': '95', 'author': 'Horita', 'year': '2023', 'journal-title': 'J Med Virol'}, { 'issue': '15', 'key': '10.1016/j.jiph.2023.10.010_bib4', 'doi-asserted-by': 'crossref', 'first-page': '1397', 'DOI': '10.1056/NEJMoa2118542', 'article-title': 'Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19', 'volume': '386', 'author': 'Hammond', 'year': '2022', 'journal-title': 'N Engl J Med'}, { 'issue': '6', 'key': '10.1016/j.jiph.2023.10.010_bib5', 'doi-asserted-by': 'crossref', 'first-page': '509', 'DOI': '10.1056/NEJMoa2116044', 'article-title': 'Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients', 'volume': '386', 'author': 'Jayk Bernal', 'year': '2022', 'journal-title': 'N Engl J Med'}, { 'key': '10.1016/j.jiph.2023.10.010_bib6', 'unstructured': 'U.S. Food and Drug Administration, FDA NEWS RELEASE, Coronavirus ' '(COVID-19) Update: FDA Authorizes First Oral Antiviral for Treatment of ' 'COVID-19 2021 [updated December 22, 2021. Available from: ' '〈https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19〉.'}, { 'issue': '3', 'key': '10.1016/j.jiph.2023.10.010_bib7', 'doi-asserted-by': 'crossref', 'first-page': '415', 'DOI': '10.1093/infdis/jiab247', 'article-title': 'β-d-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis ' 'But Is Also Mutagenic To Mammalian Cells', 'volume': '224', 'author': 'Zhou', 'year': '2021', 'journal-title': 'J Infect Dis'}, { 'issue': '1', 'key': '10.1016/j.jiph.2023.10.010_bib8', 'doi-asserted-by': 'crossref', 'first-page': '165', 'DOI': '10.1093/cid/ciac180', 'article-title': 'Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 ' 'Antiviral Drugs', 'volume': '76', 'author': 'Saravolatz', 'year': '2023', 'journal-title': 'Clin Infect Dis'}, { 'key': '10.1016/j.jiph.2023.10.010_bib9', 'unstructured': 'Department of Medical Service. Clinical Practice Guideline to Diagnosis, ' 'Treatment and Prevention COVID-19 for Physicain and Health Care ' 'Provider, 21 July 2021 2021 [Available from: ' '〈https://covid19.dms.go.th/Content/Select_Landding_page?contentId=139〉.'}, { 'issue': '1', 'key': '10.1016/j.jiph.2023.10.010_bib10', 'doi-asserted-by': 'crossref', 'first-page': '1', 'DOI': '10.1038/s41598-021-90551-6', 'article-title': 'The efficacy and safety of Favipiravir in treatment of COVID-19: A ' 'systematic review and meta-analysis of clinical trials', 'volume': '11', 'author': 'Hassanipour', 'year': '2021', 'journal-title': 'Scientific reports'}, { 'issue': '1', 'key': '10.1016/j.jiph.2023.10.010_bib11', 'doi-asserted-by': 'crossref', 'first-page': '1', 'DOI': '10.1186/s12985-020-01412-z', 'article-title': 'Favipiravir versus other antiviral or standard of care for COVID-19 ' 'treatment: a rapid systematic review and meta-analysis', 'volume': '17', 'author': 'Shrestha', 'year': '2020', 'journal-title': 'Virology journal'}, { 'issue': '1', 'key': '10.1016/j.jiph.2023.10.010_bib12', 'doi-asserted-by': 'crossref', 'first-page': 'e432', 'DOI': '10.1093/cid/ciab962', 'article-title': 'Efficacy of Early Treatment With Favipiravir on Disease Progression ' 'Among High-Risk Patients With Coronavirus Disease 2019 (COVID-19): A ' 'Randomized, Open-Label Clinical Trial', 'volume': '75', 'author': 'Chuah', 'year': '2022', 'journal-title': 'Clin Infect Dis'}, { 'key': '10.1016/j.jiph.2023.10.010_bib13', 'doi-asserted-by': 'crossref', 'DOI': '10.3389/fphar.2021.652688', 'article-title': 'Fluvoxamine: A Review of Its Mechanism of Action and Its Role in ' 'COVID-19', 'volume': '12', 'author': 'Sukhatme', 'year': '2021', 'journal-title': 'Front Pharmacol'}, { 'issue': '2', 'key': '10.1016/j.jiph.2023.10.010_bib14', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.ijantimicag.2020.106044', 'article-title': 'Widely available lysosome targeting agents should be considered as ' 'potential therapy for COVID-19', 'volume': '56', 'author': 'Homolak', 'year': '2020', 'journal-title': 'Int J Antimicrob Agents'}, { 'key': '10.1016/j.jiph.2023.10.010_bib15', 'doi-asserted-by': 'crossref', 'first-page': '34', 'DOI': '10.1016/j.virol.2019.05.002', 'article-title': 'The ER stress sensor IRE1 and MAP kinase ERK modulate autophagy ' 'induction in cells infected with coronavirus infectious bronchitis ' 'virus', 'volume': '533', 'author': 'Fung', 'year': '2019', 'journal-title': 'Virology'}, { 'issue': '3', 'key': '10.1016/j.jiph.2023.10.010_bib16', 'doi-asserted-by': 'crossref', 'first-page': '149', 'DOI': '10.2165/00129784-200303030-00001', 'article-title': 'Effect of selective serotonin reuptake inhibitors on platelet ' 'activation: can they prevent acute myocardial infarction?', 'volume': '3', 'author': 'Schlienger', 'year': '2003', 'journal-title': 'Am J Cardiovasc Drugs'}, { 'issue': '2', 'key': '10.1016/j.jiph.2023.10.010_bib17', 'doi-asserted-by': 'crossref', 'first-page': '114', 'DOI': '10.37201/req/122.2022', 'article-title': 'Insights for COVID-19 in 2023', 'volume': '36', 'author': 'Martín Sánchez', 'year': '2023', 'journal-title': 'Rev Esp Quimioter'}, { 'issue': '22', 'key': '10.1016/j.jiph.2023.10.010_bib18', 'doi-asserted-by': 'crossref', 'first-page': '2292', 'DOI': '10.1001/jama.2020.22760', 'article-title': 'Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With ' 'Symptomatic COVID-19: A Randomized Clinical Trial', 'volume': '324', 'author': 'Lenze', 'year': '2020', 'journal-title': 'Jama.'}, { 'issue': '5', 'key': '10.1016/j.jiph.2023.10.010_bib19', 'doi-asserted-by': 'crossref', 'first-page': '1315', 'DOI': '10.4269/ajtmh.21-1310', 'article-title': 'Fluvoxamine for the Early Treatment of COVID-19: A Meta-analysis of ' 'Randomized Clinical Trials', 'volume': '106', 'author': 'Guo', 'year': '2022', 'journal-title': 'Am J Trop Med Hyg'}, { 'issue': '1', 'key': '10.1016/j.jiph.2023.10.010_bib20', 'doi-asserted-by': 'crossref', 'first-page': 'e42', 'DOI': '10.1016/S2214-109X(21)00448-4', 'article-title': 'Effect of early treatment with fluvoxamine on risk of emergency care ' 'and hospitalisation among patients with COVID-19: the TOGETHER ' 'randomised, platform clinical trial', 'volume': '10', 'author': 'Reis', 'year': '2022', 'journal-title': 'Lancet Glob Health'}, { 'issue': '1', 'key': '10.1016/j.jiph.2023.10.010_bib21', 'doi-asserted-by': 'crossref', 'first-page': '102', 'DOI': '10.3947/ic.2021.0142', 'article-title': 'Fluvoxamine Treatment of Patients with Symptomatic COVID-19 in a ' 'Community Treatment Center: A Preliminary Result of Randomized ' 'Controlled Trial', 'volume': '54', 'author': 'Seo', 'year': '2022', 'journal-title': 'Infect Chemother'}, { 'issue': '4', 'key': '10.1016/j.jiph.2023.10.010_bib22', 'doi-asserted-by': 'crossref', 'DOI': '10.1001/jamanetworkopen.2022.6269', 'article-title': 'Fluvoxamine for Outpatient Management of COVID-19 to Prevent ' 'Hospitalization: A Systematic Review and Meta-analysis', 'volume': '5', 'author': 'Lee', 'year': '2022', 'journal-title': 'JAMA Netw Open'}, { 'key': '10.1016/j.jiph.2023.10.010_bib23', 'article-title': 'Fluvoxamine for Outpatient Treatment of COVID-19: A Decentralized, ' 'Placebo-controlled, Randomized, Platform Clinical Trial', 'author': 'McCarthy', 'year': '2022', 'journal-title': 'medRxiv'}, { 'issue': '2', 'key': '10.1016/j.jiph.2023.10.010_bib24', 'doi-asserted-by': 'crossref', 'first-page': 'ofab050', 'DOI': '10.1093/ofid/ofab050', 'article-title': 'Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus ' 'Disease 19', 'volume': '8', 'author': 'Seftel', 'year': '2021', 'journal-title': 'Open Forum Infect Dis'}, { 'issue': '5', 'key': '10.1016/j.jiph.2023.10.010_bib25', 'doi-asserted-by': 'crossref', 'first-page': '2065', 'DOI': '10.1111/bcp.15126', 'article-title': 'Safety and efficacy of fluvoxamine in COVID-19 ICU patients: An open ' 'label, prospective cohort trial with matched controls', 'volume': '88', 'author': 'Calusic', 'year': '2022', 'journal-title': 'Br J Clin Pharmacol'}, { 'key': '10.1016/j.jiph.2023.10.010_bib26', 'doi-asserted-by': 'crossref', 'first-page': '211', 'DOI': '10.1016/j.ijid.2023.06.018', 'article-title': 'Efficacy of combination therapy of fluvoxamine and favipiravir vs ' 'favipiravir monotherapy to prevent severe COVID-19 among mild to ' 'moderate COVID-19 patients: Open-label randomized controlled trial ' '(EFFaCo study)', 'volume': '134', 'author': 'Siripongboonsitti', 'year': '2023', 'journal-title': 'Int J Infect Dis'}, { 'issue': '11-12', 'key': '10.1016/j.jiph.2023.10.010_bib27', 'doi-asserted-by': 'crossref', 'first-page': '389', 'DOI': '10.18071/isz.74.0389', 'article-title': 'Fluoxetine use is associated with improved survival of patients with ' 'COVID-19 pneumonia: A retrospective case-control study', 'volume': '74', 'author': 'Németh', 'year': '2021', 'journal-title': 'Ideggyogy Sz'}, { 'issue': '9', 'key': '10.1016/j.jiph.2023.10.010_bib28', 'doi-asserted-by': 'crossref', 'first-page': '5199', 'DOI': '10.1038/s41380-021-01021-4', 'article-title': 'Association between antidepressant use and reduced risk of intubation ' 'or death in hospitalized patients with COVID-19: results from an ' 'observational study', 'volume': '26', 'author': 'Hoertel', 'year': '2021', 'journal-title': 'Mol Psychiatry'}, { 'issue': '1', 'key': '10.1016/j.jiph.2023.10.010_bib29', 'doi-asserted-by': 'crossref', 'first-page': '56', 'DOI': '10.1016/j.bpsgos.2021.12.007', 'article-title': 'Risk of Death in Individuals Hospitalized for COVID-19 With and Without ' 'Psychiatric Disorders: An Observational Multicenter Study in France', 'volume': '3', 'author': 'Hoertel', 'year': '2023', 'journal-title': 'Biol Psychiatry Glob Open Sci'}, { 'issue': '11', 'key': '10.1016/j.jiph.2023.10.010_bib30', 'doi-asserted-by': 'crossref', 'DOI': '10.1001/jamanetworkopen.2021.33090', 'article-title': 'Mortality Risk Among Patients With COVID-19 Prescribed Selective ' 'Serotonin Reuptake Inhibitor Antidepressants', 'volume': '4', 'author': 'Oskotsky', 'year': '2021', 'journal-title': 'JAMA Netw Open'}], 'container-title': 'Journal of Infection and Public Health', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S1876034123003374?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://api.elsevier.com/content/article/PII:S1876034123003374?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'deposited': { 'date-parts': [[2023, 10, 7]], 'date-time': '2023-10-07T08:55:42Z', 'timestamp': 1696668942000}, 'score': 1, 'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S1876034123003374'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2023, 10]]}, 'references-count': 30, 'alternative-id': ['S1876034123003374'], 'URL': 'http://dx.doi.org/10.1016/j.jiph.2023.10.010', 'relation': {}, 'ISSN': ['1876-0341'], 'subject': [ 'Infectious Diseases', 'Public Health, Environmental and Occupational Health', 'General Medicine'], 'container-title-short': 'Journal of Infection and Public Health', 'published': {'date-parts': [[2023, 10]]}, 'assertion': [ {'value': 'Elsevier', 'name': 'publisher', 'label': 'This article is maintained by'}, { 'value': 'The Real-World Effectiveness of Fluvoxamine Therapy in Mild to Moderate ' 'COVID-19 Patients; a Historical Cohort Study (Fluvoxa Trial)', 'name': 'articletitle', 'label': 'Article Title'}, { 'value': 'Journal of Infection and Public Health', 'name': 'journaltitle', 'label': 'Journal Title'}, { 'value': 'https://doi.org/10.1016/j.jiph.2023.10.010', 'name': 'articlelink', 'label': 'CrossRef DOI link to publisher maintained version'}, {'value': 'article', 'name': 'content_type', 'label': 'Content Type'}, { 'value': '© 2023 The Author(s). Published by Elsevier Ltd on behalf of King Saud Bin ' 'Abdulaziz University for Health Sciences.', 'name': 'copyright', 'label': 'Copyright'}]}